Daiichi Sankyo Company, Limited (DSKYF)

Market Cap	35.65B -33.4%
Revenue (ttm)	13.09B +14.3%
Net Income	1.94B +23.9%
EPS	1.04 +27.1%
Shares Out	n/a
PE Ratio	18.35
Forward PE	n/a
Dividend	0.51 (2.76%)
Ex-Dividend Date	Mar 30, 2026

Volume	1,200
Average Volume	96,757
Open	18.81
Previous Close	18.62
Day's Range	18.81 - 18.97
52-Week Range	17.41 - 29.15
Beta	-0.33
RSI	45.03
Earnings Date	Jan 30, 2026

About Daiichi Sankyo Company

Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, the United States, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule that targets colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation for the treatment ...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1899
• Employees: 19,765
• Stock Exchange: OTCMKTS
• Ticker Symbol: DSKYF

Financial Performance

In fiscal year 2025, Daiichi Sankyo Company's revenue was 1.89 trillion, an increase of 17.77% compared to the previous year's 1.60 trillion. Earnings were 295.76 billion, an increase of 47.34%.

Financial numbers in JPY